Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.
Nanoviricides, Inc. (NNVC) is a clinical-stage biopharmaceutical company pioneering antiviral therapies using proprietary nanomedicine technology. This page serves as the definitive source for verified news and official updates regarding the company's innovative drug development programs.
Investors and researchers will find comprehensive coverage of NNVC's progress including clinical trial developments, regulatory milestones, and strategic partnerships. Our curated collection features press releases on lead candidate NV-387's advancement through clinical studies, updates on broad-spectrum antiviral research, and collaborations advancing nanoviricide platforms.
Key content categories include scientific breakthroughs in host-mimetic nanotechnology, FDA regulatory communications, financial reporting disclosures, and analysis of NNVC's position within the antiviral therapeutics market. All materials are sourced directly from company filings and authorized statements to ensure reliability.
Bookmark this page for streamlined access to NNVC's latest developments in nanoscale antiviral solutions. Check regularly for updates on clinical programs targeting respiratory viruses, herpes-related infections, and other viral pathogens through NNVC's novel therapeutic approach.
NanoViricides, Inc. (NNVC) is advancing its antiviral drug candidate NV-387, originally developed for COVID-19, to explore broader applications against various viral infections. Pre-clinical studies show NV-387 exhibits activity against seasonal coronaviruses and SARS-CoV-2, aiming to serve as a broad-spectrum antiviral agent. The drug targets virus particles similarly to antibiotics targeting bacteria, with potential effectiveness against viruses like RSV and others. After successful Phase 1 trials, NV-387 could enter Phase 2 trials for multiple viral diseases, potentially optimizing development costs. Currently, the company is also focusing on therapeutics for the poxvirus family and other respiratory viruses, addressing the unmet need for safe and effective antiviral treatments.
NanoViricides, Inc. (NYSE American: NNVC) announced the shipment of drug products for the clinical trials of NV-CoV-2, its COVID-19 drug candidate, to collaborator Karveer Meditech Pvt. Ltd. in India. Karveer has secured regulatory approvals to conduct these trials, which are expected to start soon. NV-CoV-2 is designed to target SARS-CoV-2 and its evolving variants and has shown broad-spectrum efficacy and strong safety in preclinical studies. The drug will be available in oral syrup and gummies, as well as injectable and infusion forms for various patient populations. Unlike current antiviral treatments, NV-CoV-2 aims to treat all segments of the population, addressing unmet medical needs in the ongoing COVID-19 pandemic.
NanoViricides has signed a License Agreement with Karveer Meditech Pvt. Ltd. for the commercialization of its COVID drugs NV-CoV-2 and NV-CoV-2-R in India. Karveer will oversee the clinical development and has reportedly obtained necessary regulatory permissions. The human clinical trials are anticipated to commence shortly. Under the agreement, Karveer will conduct evaluations in compliance with local regulations, while NanoViricides retains rights to the data generated. Upon commercialization, NanoViricides will earn a 70% royalty on sales. This marks a significant milestone for the company in advancing its antiviral therapies.
FAQ
What is the current stock price of Nanoviricides (NNVC)?
What is the market cap of Nanoviricides (NNVC)?
